Paolo Ghia
机构: Professor of Medical Oncology, Università Vita-Salute San Raffaele
主页: unisr.it
每年引用次数
引用次数
引用: 39,491
H-指数: 99
I10-指数 : 358
出版物: 1,110
DNA methylation profiling in chronic lymphocytic leukemia patients carrying stereotyped B-cell receptors: a different cellular origin for subset #2?
S. Ntoufa , S. Pospisilova , Richard Rosenquist , D. Oscier
Haematologica 102 68 -68
2017
CYTOGENETIC COMPLEXITY IN CHRONIC LYMPHOCYTIC LEUKEMIA : DEFINITIONS, ASSOCIATIONS WITH OTHER BIOMARKERS AND CLINICAL IMPACT; A RETROSPECTIVE STUDY ON BEHALF OF ERIC
N. Stavroyianni , C. Haferlach , E. Stalika , S. Pospisilova
Haematologica 102 170 -170
2
2017
B-cell development in mouse and man
E. Ten Boekel , F. Melchers , H. Karasuyama , P. Ghia
Immunologist 3 ( 4) 125 -128
15
1995
Molecular mechanisms of B cell disorders
D. Gottardi , A. Novarino , P. Ghia , L. Bergui
Immunologia Clinica 11 ( 4) 131 -137
1992
Valutazione immunofenotipica nelle malattie onco-ematologiche acute e croniche
M. Chilosi , P. Ghia , Mauro Krampera
Giorgio Lambertenghi Deliliers 2
2007
RNASET2 is a non-cell autonomous human tumor suppressor
Annalisa Grimaldi , I Raimondi , Carlo Renato Capella , Francesco Acquati
FISV- Federazione Italiana Scienza della Vita
2008
DISSECTING RESISTANCE MECHANISMS IN CHRONIC LYMPHOCYTIC LEUKEMIA USING WHOLE-EXOME SEQUENCING : IMPACT OF RECURRENT RPS15 MUTATIONS ON P53 DYSREGULATION
N. Stavroyianni , Viktor Ljungström , S. Pospisilova , Richard Rosenquist
Haematologica 100 10 -11
2015
AN ONGOING PHASE 2 STUDY OF IBRUTINIB COMBINED WITH VENETOCLAX IN PATIENTS WITH TREATMENT-NAÏVE CLL/SLL
P. Ghia , C.S. Tam , T. Siddiqi , D. Stevens
Hematological Oncology 35 428 -428
1
2017
A MRD‐GUIDED APPROACH FOR THE COMBINATION OF IBRUTINIB TO VENETOCLAX IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (IMPROVE STUDY)
P. Ghia , L. Scarfò , M. Coscia , R. Sancetta
Hematological Oncology 35 426 -427
2017
EFFECT OF SINGLE-AGENT IBRUTINIB ON TUMOR DEBULKING AND REDUCTIONS IN TUMOR LYSIS SYNDROME (TLS) RISK IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
C.S. Tam , J.C. Byrd , S. O'Brien , S. Coutre
Hematological Oncology 35 233 -234
2017
Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation.
P. Ghia , N. Chiorazzi , K. Stamatopoulos
Journal of Internal Medicine 264 ( 6) 549 -562
147
2008
Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNase
F. Acquati , S. Bertilaccio , A. Grimaldi , L. Monti
Proceedings of the National Academy of Sciences of the United States of America 108 ( 3) 1104 -1109
47
2011
PP-054 EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
J. Sharman , S. Coutre , R. Furman , B. Cheson
Leukemia Research 38
1
2014
4.25 Update on the International Standardized Approach for Flow Cytometric Residual Disease Monitoring in CLL
A.C. Rawstron , S. Böttcher , R. Letestu , N. Villamor
Clinical Lymphoma Myeloma and Leukemia 11 S235 -S236
2011
Management of chronic lymphocytic leukemia
P. Ghia , M. Hallek
Haematologica 99 ( 6) 965 -972
30
2014
SIGLEC-G deficiency increases susceptibility to develop B-cell lymphoproliferative disorders.
G. Simonetti , M. T. S. Bertilaccio , T. V. Rodriguez , B. Apollonio
Haematologica 99 ( 8) 1356 -1364
5
2014
MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis
P. Soderkvist , M. Linderholm , D. Oscier , Z. Tvaruzkova
Haematologica 99 ( 8) 1285 -1291
2
2014
Bendamustine and subcutaneous Alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients
M. Montillo , A. Tedeschi , G. Gaidano , M. Coscia
Haematologica 99 ( 9) 159 -161
6
2014
Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting
L.-A. Sutton , V. Ljungstrom , L. Mansouri , E. Young
Haematologica 100 ( 3) 370 -376
42
2015
Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation.
E. Fonte , A. Agathangelidis , D. Reverberi , S. Ntoufa
Haematologica 100 ( 11) 1460 -1468
12
2015